Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)
Anibh Martin Das Department of Pediatrics, Hannover Medical School, Hannover, Germany Abstract: Medical therapy for hereditary hepatorenal tyrosinemia (hereditary tyrosinemia type 1, HT-1) with nitisinone was discovered incidentally, and is a by-product of agrochemistry. It blocks the catabolic path...
Main Author: | Das AM |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-07-01
|
Series: | The Application of Clinical Genetics |
Subjects: | |
Online Access: | https://www.dovepress.com/clinical-utility-of-nitisinone-for-the-treatment-of-hereditary-tyrosin-peer-reviewed-article-TACG |
Similar Items
-
Type 1 tyrosinemia in Finland: a nationwide study
by: Linnea Äärelä, et al.
Published: (2020-10-01) -
Clinical and para clinical findings in the children with tyrosinemia referring for liver transplantation
by: Seyed Mohsen Dehghani, et al.
Published: (2013-01-01) -
Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review
by: Julia Geppert, et al.
Published: (2017-09-01) -
The Importance of Succinylacetone: Tyrosinemia Type I Presenting with Hyperinsulinism and Multiorgan Failure Following Normal Newborn Screening
by: Jessica R. C. Priestley, et al.
Published: (2020-05-01) -
Inter‐laboratory analytical improvement of succinylacetone and nitisinone quantification from dried blood spot samples
by: Hilde Laeremans, et al.
Published: (2020-05-01)